Movement Alert｜ZAI LAB Rises 5.02% in Regular Trading, Efgartigimod Phase 3 Trial in Autoimmune Myositis Achieves Positive Results

Market Focus

Aug 20

On August 20, ZAI LAB rose 5.02% in regular trading, trading at HKD 21.34/share, with turnover of HKD 168 million.

On the news front, partner argenx announced on August 17 that its core product, FcRn antagonist efgartigimod, achieved positive topline results in the ALKIVIA Phase 3 clinical study for the treatment of adult autoimmune myositis. argenx has previously granted ZAI LAB exclusive rights to develop and commercialize efgartigimod in Greater China, and ZAI LAB participated in the Greater China clinical development and patient enrollment for this global study.

Clinical data showed patient improvement was evident early in treatment and sustained throughout the study period, with highly consistent treatment effects observed across both immune-mediated necrotizing myopathy and dermatomyositis subgroups. If this indication receives subsequent regulatory approval, ZAI LAB is expected to further expand efgartigimod's commercial footprint in China's autoimmune disease market. Notably, major shareholder RTW Investments recently increased its stake by approximately 4.77 million shares at USD 25.41 per share, reflecting institutional confidence in the company's pipeline.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/1168020847"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168020847\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168020847?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-20 11:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168020847","market":"hk","top_or_hot":-1,"title":"Movement Alert｜ZAI LAB Rises 5.02% in Regular Trading, Efgartigimod Phase 3 Trial in Autoimmune Myositis Achieves Positive Results","media":"Market Focus","content":"<p><p>On August 20, ZAI LAB rose 5.02% in regular trading, trading at HKD 21.34/share, with turnover of HKD 168 million.</p><p>On the news front, partner argenx announced on August 17 that its core product, FcRn antagonist efgartigimod, achieved positive topline results in the ALKIVIA Phase 3 clinical study for the treatment of adult autoimmune myositis. argenx has previously granted ZAI LAB exclusive rights to develop and commercialize efgartigimod in Greater China, and ZAI LAB participated in the Greater China clinical development and patient enrollment for this global study.</p><p>Clinical data showed patient improvement was evident early in treatment and sustained throughout the study period, with highly consistent treatment effects observed across both immune-mediated necrotizing myopathy and dermatomyositis subgroups. If this indication receives subsequent regulatory approval, ZAI LAB is expected to further expand efgartigimod's commercial footprint in China's autoimmune disease market. Notably, major shareholder RTW Investments recently increased its stake by approximately 4.77 million shares at USD 25.41 per share, reflecting institutional confidence in the company's pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜ZAI LAB Rises 5.02% in Regular Trading, Efgartigimod Phase 3 Trial in Autoimmune Myositis Achieves Positive Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜ZAI LAB Rises 5.02% in Regular Trading, Efgartigimod Phase 3 Trial in Autoimmune Myositis Achieves Positive Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-08-20 11:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On August 20, ZAI LAB rose 5.02% in regular trading, trading at HKD 21.34/share, with turnover of HKD 168 million.</p><p>On the news front, partner argenx announced on August 17 that its core product, FcRn antagonist efgartigimod, achieved positive topline results in the ALKIVIA Phase 3 clinical study for the treatment of adult autoimmune myositis. argenx has previously granted ZAI LAB exclusive rights to develop and commercialize efgartigimod in Greater China, and ZAI LAB participated in the Greater China clinical development and patient enrollment for this global study.</p><p>Clinical data showed patient improvement was evident early in treatment and sustained throughout the study period, with highly consistent treatment effects observed across both immune-mediated necrotizing myopathy and dermatomyositis subgroups. If this indication receives subsequent regulatory approval, ZAI LAB is expected to further expand efgartigimod's commercial footprint in China's autoimmune disease market. Notably, major shareholder RTW Investments recently increased its stake by approximately 4.77 million shares at USD 25.41 per share, reflecting institutional confidence in the company's pipeline.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09688","symbol_name":"再鼎医药","start_time":0,"source_url":"","article_id":"1168020847","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168020847","pubTimestamp":1787196929,"columns":[{"name":"Data Report","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On August 20, ZAI LAB rose 5.02% in regular trading, trading at HKD 21.34/share, with turnover of HKD 168 million.On the news front, partner argenx announced on August 17 that its core product, FcRn...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09688":"再鼎医药"},"translate_title":"异动预警|再鼎医药常规交易大涨5.02%，Efgartigimod自身免疫性肌炎3期试验取得积极成果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09688":1},"content_text":"On August 20, ZAI LAB rose 5.02% in regular trading, trading at HKD 21.34/share, with turnover of HKD 168 million.On the news front, partner argenx announced on August 17 that its core product, FcRn antagonist efgartigimod, achieved positive topline results in the ALKIVIA Phase 3 clinical study for the treatment of adult autoimmune myositis. argenx has previously granted ZAI LAB exclusive rights to develop and commercialize efgartigimod in Greater China, and ZAI LAB participated in the Greater China clinical development and patient enrollment for this global study.Clinical data showed patient improvement was evident early in treatment and sustained throughout the study period, with highly consistent treatment effects observed across both immune-mediated necrotizing myopathy and dermatomyositis subgroups. If this indication receives subsequent regulatory approval, ZAI LAB is expected to further expand efgartigimod's commercial footprint in China's autoimmune disease market. Notably, major shareholder RTW Investments recently increased its stake by approximately 4.77 million shares at USD 25.41 per share, reflecting institutional confidence in the company's pipeline.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}